The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Psoriasis researchers identify a lineup of suspect proteins behind disease progression

The recent approval of Novartis' Cosentyx marks the first in a whole new lineup of psoriasis drugs coming into the market. But there's still no cure and only a hazy understanding of the root causes of psoriasis. But scientists at Case Western Reserve say they've identified four proteins that they believe may contribute to the disease.

Novartis Q4 profit slumps nearly 27% as sales take a hit

Swiss-based Novartis reported a nearly 27% drop in fourth-quarter profit on Tuesday as lower-than-expected sales hit the bottom line.

Novartis hands off another PhIII drug to Array

That big drug swap between Novartis and GlaxoSmithKline is once again proving to be a boon to Array BioPharma. Array saw its shares spike more than 40% on Friday after the company said that Novartis is handing back rights to the Phase III BRAF inhibitor encorafenib, not long after it also scooped up the rights to binimetinib.

Ready to spar with Pfizer's meningitis B jab, Novartis gets FDA green light for Bexsero

Novartis has long pinned its hopes on meningitis B shot Bexsero to revitalize its lagging vaccines unit. Now, the company is celebrating the product's FDA approval, even as it prepares to hand off the jab to GlaxoSmithKline in a blockbuster asset swap.

Manufacturing key to getting more effective flu jabs to market faster

With the effectiveness of this year's influenza vaccines so low as to have made most of this year's vaccinations pointless, the industry is searching for avenues to abbreviate the 6-month development and manufacturing process to deal better with the kinds of virus mutations that came into play this year.

After rocky flu season, vaccinemakers may want to follow Novartis' lead

Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.

Novartis eyes psoriasis dominance with new approvals for Cosentyx

Novartis scored FDA and European approvals this week for its blockbuster contender Cosentyx. But rival companies are developing their own therapies, and existing drugs challenge its market share.

Strong dollar plus strong franc equals worries for global Big Pharma

When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche and Novartis. And now, Johnson & Johnson's fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.

UPDATED: Novartis scores the first victory in a blockbuster psoriasis race

Novartis picked up FDA and European approvals to sell its secukinumab as a treatment for psoriasis, the first steps in the company's plot to build a global anti-inflammatory contender and outpace its rivals.

Novartis Puerto Rico cut in consumer JV with GSK

When Novartis announced plans to hand off its consumer health operations to a joint venture with GlaxoSmithKline, the companies said they figured they could save a boatload of money in "synergies." It looks like a small part of that will come from closing a Novartis plant in Puerto Rico that makes consumer and veterinary products, shedding 270 jobs in the process.